Douglas Flora: Launching The Augmented Oncologist on Substack
Douglas Flora, Executive Medical Director of Oncology Services at St. Elizabeth Healthcare, shared a post on LinkedIn:
“Big News.
Launching The Augmented Oncologist on Substack.
When I started sharing my thoughts on LinkedIn just over a year ago, something unexpected happened: I rediscovered my love of writing.
It was like finding an old friend I didn’t realize I’d missed so much. And wow—over 1,000,000 impressions later (still can’t believe that number), you’ve shown me there’s a real hunger for clear, practical insights about AI in cancer care.
So I’m taking the next step.
Introducing The Augmented Oncologist – your weekly navigation system for the rapidly evolving world of AI in healthcare.
Here’s what you’ll get:
- Clear, digestible updates on the week’s most important AI developments.
- Real-world context on what these changes mean for you.
- Book recommendations that have shaped my thinking.
- Leadership insights from the frontlines.
- And yes, the occasional dad joke (because cancer care is serious enough without our updates being dry).
The best part?
While subscriptions are tiered (Free to Founder levels), 100% of subscription proceeds will be distributed to 12 outstanding cancer charities.
I’ll announce each month’s featured organization right here on LinkedIn.
Why subscribe?
Because together, we can:
- Cut through the AI hype.
- Stay ahead of the curve.
- Build a community of forward-thinking healthcare professionals.
- Support vital cancer-fighting organizations
Ready to join me on this next chapter?
Click the link in my comments to subscribe.
Would love your support in sharing this with others who might find value in our growing community.”
Douglas Flora is the Executive Medical Director of Oncology Services at St. Elizabeth Healthcare, overseeing clinical operations, strategic planning, and the expansion of cancer programs. He is also the co-founder of the Center for Precision Medicine; Genomic Health and the Leader of the AI and HealthCare Team for the Cincinnati AI Catalyst (CaiC).
As the Editor-in-Chief of ‘AI in Precision Oncology,’ the first peer-reviewed academic journal dedicated to this field, he plays a pivotal role in advancing research. He is also an active board member of the American Cancer Society and ACCC, where he contributes to advocacy, education, and innovation within the cancer community.
More posts featuring Douglas Flora.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023